Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

31/03/2016 ICN2 Graphene-Based Sensors for Biomedicine and Brain-Machine Interfaces 21/03/2016 Halal Certification Awarded to Natura Bissé 16/03/2016 SENER is back to Mars 09/03/2016 Barcelona, 2016/17 Top European City for FDI Strategy 03/03/2016 NCD Beamline at ALBA Synchrotron: When X-Rays Make Chocolate Speak 24/02/2016 Barcelona DC Cluster from BSP at the 2016 Mobile World Congress Brokerage Event
26 27 28 29 30 31 32 33 34 35 36